TAM
SRPT icon

Tiverton Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Tiverton Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$113K Buy
1,503
+246
+20% +$29.1K ﹤0.01% 635
2019
Q2 		$191K Hold
1,257
– – 0.01% 564
2019
Q1 		$150K Buy
1,257
+252
+25% +$32.4K 0.01% 546
2018
Q4 		$110K Buy
+1,005
New +$126K 0.01% 358

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Tiverton Asset Management's SRPT Position: Q3 2019 in Review

Tiverton Asset Management increased its Sarepta Therapeutics (SRPT) stake by 20% in Q3 2019, buying an estimated $29.1K and bringing the position to 1,503 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #635.

Tiverton Asset Management first reported a position in SRPT in Q4 2018 and has held it in 4 quarters since. The position peaked at $191K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Tiverton Asset Management held 1,503 shares of Sarepta Therapeutics worth $113K as of Q3 2019.
  • Tiverton Asset Management bought 246 Sarepta Therapeutics shares in Q3 2019, an estimated $29.1K.
  • Sarepta Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #635 holding.
  • Tiverton Asset Management first reported a position in Sarepta Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Tiverton Asset Management's Sarepta Therapeutics position peaked at $191K in Q2 2019.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.